12:00 AM
 | 
Nov 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Relistor methylnaltrexone: Phase II started

Ono began a double-blind, placebo-controlled, Japanese Phase II trial to evaluate ONO-3849 in patients. Subcutaneous methylnaltrexone is approved in over 40 countries as Relistor to treat OIC in...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >